Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Sponsor: Tianjin Medical University General Hospital
Summary
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor that blocks the upregulated JAK-STAT pathway in patients with neuroimmune disorders, which is important in bone marrow regulation of B cell proliferation and differentiation. Baricitinib may benefit some patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD. Clinical trials may be needed to observe its efficacy and safety.
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2023-04-15
Completion Date
2025-12-30
Last Updated
2024-10-16
Healthy Volunteers
No
Conditions
Interventions
Baricitinib
Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.
Locations (1)
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China